Determinant spreading and tumor responses after peptide-based cancer immunotherapy

Trends in Immunology

Volumn 24, Issue 2, 2003, Pages 58-61

  Ribas, Antoni ^a   Timmerman, John M ^a   Butterfield, Lisa H ^a   Economou, James S ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ANTIGEN SPECIFICITY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CORRELATION FUNCTION; DRUG EFFICACY; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; MELANOMA; NONHUMAN; OVARY CARCINOMA; REVIEW; T LYMPHOCYTE; TUMOR REGRESSION; VACCINATION;

EID: 0037302519     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)00029-7     Document Type: Short Survey

References (14)

1. Sercarz E.E. Driver clones and determinant spreading. J. Autoimmun. 14:2000;275-277.
2. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2:2002;85-95.
3. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature. 411:2001;380-384.
4. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:1999;507-529.
5. Ranieri E., et al. Dendritic-cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol. Invest. 29:2000;121-125.
6. Brossart P., et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 96:2000;3102-3108.
7. Lally K.M., et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer. 93:2001;841-847.
8. Butterfield L.H., et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 2002;. in press.
9. Jonuleit H., et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer. 93:2001;243-251.
10. Disis M.L., et al. Generation of T-cell immunity to the Her-2/neu protein after active immunization with Her-2/neu peptide-based vaccines. J. Clin. Oncol. 20:2002;2624-2632.
11. Disis M.L., et al. Generation of immunity to Her-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5:1999;1289-1297.
12. Markiewicz M.A., et al. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int. Immunol. 13:2001;625-632.
13. el-Shami K., et al. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur. J. Immunol. 29:1999;3295-3301.
14. Wang H.B., et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J. Immunol. 166:2001;6430-6436.